Labcorp Holdings Inc. (LH) · Sep 10, 2026 · Guidance

Labcorp reaffirms 2026 guidance, but 2029 targets offer few fresh surprises

Guidance reaffirmed — FY2026 adjusted EPS $18.10-$18.55 vs ~$18.32 consensus

Labcorp kept its 2026 outlook unchanged and introduced 2029 growth targets. The update adds a framework, not a clear earnings surprise.

The 2026 outlook is unchanged and broadly in line with expectations. Labcorp reaffirmed guidance last updated on July 30, rather than raising it again. 〔0〕 The adjusted EPS range of $18.10-$18.55 brackets the published consensus of roughly $18.32, putting the midpoint essentially on expectation.

Metric2026 guidanceComparison
Enterprise revenue$14,710-$14,827 million5.4%-6.3% growth; 2025 revenue $13,952 million (Guidance table)
Diagnostics Laboratories revenue$11,450-$11,532 million5.3%-6.0% growth; 2025 revenue $10,876 million (Guidance table)
Biopharma Laboratory Services revenue$3,269-$3,300 million5.5%-6.5% growth; 2025 revenue $3,098 million (Guidance table)
Adjusted EPS$18.10-$18.55Consensus approximately $18.32
Free cash flow$1,240-$1,360 millionNo clean published benchmark provided

The genuinely new information is the long-term framework, not a near-term reset. Through 2029, management expects revenue to compound at 5%-8% annually and adjusted EPS at 8.5%-11.5%, with 75-150 basis points of adjusted operating-margin expansion. 〔1〕 Those targets broadly extend the company's existing high-single-digit EPS-growth narrative rather than introducing a materially higher ambition.

The net read is confirmation, not a beat. The investor-day event was scheduled and the 2026 guidance had already been disclosed, so the filing mainly removes downside risk while giving investors a longer planning horizon. With no guidance increase and no clear evidence that the 2029 range exceeds the market's standing assumptions, the appropriate scorecard is reaffirmed guidance rather than positive surprise.

What to watch next

Q3 earnings report, late October

Original filing on SEC EDGAR

More Labcorp Holdings Inc. news

Labcorp reaffirms 2026 guidance, but 2029 targets offer few fresh surprises | LH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.